Celltrion's ZYMFENTRA Shows Efficacy in Crohn's Disease Study
Celltrion's ZYMFENTRA® Demonstrates Efficacy in Crohn's Disease Celltrion, Inc. has recently published promising results from a post-hoc analysis of the LIBERTY-CD study regarding ZYMFENTRA® (infliximab-dyyb). This analysis reveals significant findings about the efficacy of ZYMFENTRA in treating Crohn's disease (CD), regardless of disease location, and it's exciting...
Continue Reading